E-ISSN 2602-3164
EJMI. 2023; 7(2): 130-136 | DOI: 10.14744/ejmi.2023.86631

Relationship Between Glucose-To-Lymphocyte, Albumin-ToAlkaline Phosphatase and Neutrophil-To-Lymphocyte Rat and Prognosis in Young Patients with Pancreatic Cancer

Engin Kut1
1Medical Oncology Clinic of Manisa State Hospital, Manisa, Türkiye

Objectives: Younger patients with cancer are usually diagnosed at a more advanced stage and have a more aggressive clinic; however, it tolerates chemotherapy better. Therefore, the prognosis of elder and young patients may be different. Glucose-to-lymphocyte (GLR), neutrophil-to-lymphocyte ratio (NLR), and albumin-to-alkaline phosphatase and neutrophil-to-lymphocyte ratio (AAPR) have been previously associated with prognosis in many cancers. There is no study evaluating the relationship between GLR, NLR, AAPR and prognosis in pancreatic cancer aged under 65 years. Therefore, we conducted this study to determine whether there is such a relationship. Methods: A total of 101 patients between 2009 and 2020 were evaluated retrospectively. Results: High GLR, NLR, and Low AAPR patients had a poor prognosis. The results of the multivariate analysis were as follows: GLR [hazard ratio(HR) for OS 1.97, p=0.041) and HR for PFS 1.90, p=0.043], NLR (HR for OS 1.535, p=0.049 and HR for PFS 1.62, p=0.045), and AAPR (1.597 for OS, p=0.046 and HR for PFS 1.99, p=0.39). Conclusion: GLR, NLR, and AAPR were associated with the prognosis of pancreatic cancer in our study. They can be used as easy, cheap and practical biomarkers to determine the monitoring treatment and prognosis of patients with pancreatic cancer. Keywords: Glucose-to-lymphocyte ratio, albumin-to-alkaline phosphatase ratio, neutrophil-to-lymphocyte ratio, pancreatic cancer, prognosis


Cite This Article

Kut E. Relationship Between Glucose-To-Lymphocyte, Albumin-ToAlkaline Phosphatase and Neutrophil-To-Lymphocyte Rat and Prognosis in Young Patients with Pancreatic Cancer. EJMI. 2023; 7(2): 130-136

Corresponding Author: Engin Kut

Full Text PDF PDF Download
EJMI & EJMI